Sector: MedicalYM BioSciences, Inc. (AMEX: YMI)
Headlines
- YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Nov 23, 2009 05:00 PM | YMI
- YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
Nov 18, 2009 12:53 PM | YMI
- YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING
Nov 17, 2009 07:01 AM | YMI
- YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Nov 11, 2009 05:02 PM | YMI
- YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
Nov 02, 2009 02:09 PM | YMI
- YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Oct 29, 2009 05:30 PM | YMI
- YM BIOSCIENCES INC. - YM BioSciences announces offer
Oct 06, 2009 02:02 AM | YMI
- Cytopia Merger with Toronto-based YM BioSciences Inc.
Oct 05, 2009 09:30 PM | YMI
- YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
Oct 05, 2009 06:31 PM | YMI
- Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities
Sep 29, 2009 03:36 PM | ACCP, ALTH, BBI, BIIB, CTIC, MEDX
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
YMI
|
Compare to S&P
|
| YTD |
227.20 %
|
170.80 %
|
| 4 Weeks |
-4.72 %
|
-5.75 %
|
| 12 Weeks |
-35.98 %
|
-39.64 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -20.00 %
|
|
EPS Growth in Last Year: -20.00 %
|
|
Sales Growth in Last Quarter: -2.88 %
|
|
Sales Growth in Last Quarter: -55.67 %
|
|
